Abiopharma

🔍 Wassil Jim (Executive)

Company: Vaxcyte, Inc. (PCVX)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Sold 1,412 shares of Common Stock at $58.138 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 165,406.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 838 shares of Common Stock at $58.932 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 162,994.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4

Footnotes:

• F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
• F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $57.695 to $58.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
• F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $58.74 to $59.215. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
• F4: The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the "Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. On March 25 and 26, 2026, the Reporting Person transferred 962 and 612 shares, respectively, of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings.